FDA COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) Initiative: Summary Report   [open pdf - 1MB]

From the Foreword: "The COVID-19 [coronavirus disease 2019] pandemic represents the most profound disruption to daily life in generations. It has reshaped our lives, forcing us to adapt the ways in which we live and work, producing enormous economic hardships, and causing profound personal pain and tragedy - with more than 350,000 deaths and 20 million confirmed cases in the United States alone - and contributed to enormous economic dislocation all over the world. The U.S. Food and Drug Administration (FDA or the 'Agency') has been at the forefront of the nation's response to the pandemic. Our resourceful and resilient workforce of nearly 18,000 strong has continued to make unparalleled contributions and demonstrated unwavering commitment to promote and protect the health and safety of the American public. As the pandemic evolves, there are beacons of hope that we must not lose sight of, including the FDA's emergency use authorization of COVID-19 vaccines, monoclonal antibody therapies, and rapid, more readily accessible tests for COVID-19, such as over-the-counter diagnostic tests. [...] The ideas presented in this report serve as a summary of potential options for the Agency to consider and are deliberative, not exhaustive, and not binding. The potential actions reflect lessons learned from the response so far and serve as a basis for continued learning and progress through and beyond the current pandemic."

Public Domain
Retrieved From:
U.S. Food and Drug Administration: https://www.fda.gov/
Media Type:
Help with citations